Considering Janus kinase inhibitors' effect on risk of thrombosis (https://acrabstracts.org/abstract/risk-of-thromboembolism-with-janus-ki…), is there cause for concern about hypercoagulability (https://doi.org/10.1111/jth.14849) in COVID-19 patients who have been receiving them? Should this issue be taken into account as we compose recommendations for our patients?